NASDAQ:VRTX
Vertex Pharmaceuticals Inc. (VRTX)
514.99
+4.27 (0.84%)
as of Sep 22, 2026, 8:00:00 pm Market Open.
79 watching
Financials 
Technical Analysis 0
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
Premium contentPAST TOP PICK
Premium contentPAST TOP PICK
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly We again reiterate this long known developer of treatment for cystic fibrosis as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases such as Type I diabetes and muscular dystrophy. Recently reported earnings beat analyst expectations by 30% and the company maintains a ROE of 31%. We also like how the company has continued to increase cash reserves, while buying back stock. We recommend trailing up the stop (from $185) to $200, looking to achieve $258 -- upside potential over 16%. Yield 0% (Analysts’ price target is $257.41)
Pharma & Healthcare
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly This long known developer of treatment for cystic fibrosis is again reiterated as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases and has recently announced success with an oral kidney treatment drug. We like how the company has continued to increase cash reserves, while paying down debt and buying back stock. We recommend trailing up the stop (from $165) to $185, looking to achieve $255 -- upside potential over 22%. Yield 0% (Analysts’ price target is $254.19)
Pharma & Healthcare
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly VRTX is a previous Top Pick that had two setbacks that caused us to recommend moving to the sidelines. However, its diversified portfolio of therapeutic drugs continues to play a leading role in the potential treatment of cystic fibrosis worldwide. It trades at 17x earning compared to peers at 43x. It has been adding cash reserves that are now estimated to exceed $8 billion. We would buy this with a stop loss at $165, looking to achieve $275 -- upside over 46%. Yield 0% (Analysts’ price target is $275.86)
Pharma & Healthcare
Premium contentPAST TOP PICK
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly VRTX is a pharmaceutical company that is world renowned in its treatment for cystic fibrosis. The company is estimated to have increased its cash position by almost $2 billion, leaving it plenty in the tank to develop other life changing drugs likes ones being developed for sickle cell disease and AAT deficiency. We would buy this with a stop-loss at $200, looking to achieve $290 -- over 25% upside potential. Yield 0% (Analysts’ price target is $289.66)
Pharma & Healthcare
Showing 31 to 40 of 40 entries
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
